ClinicalTrials.gov
ClinicalTrials.gov Menu

Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00444665
Recruitment Status : Completed
First Posted : March 8, 2007
Last Update Posted : November 21, 2016
Sponsor:
Information provided by (Responsible Party):
Alcon Research

Brief Summary:
Examine the safety, tolerability and efficacy of travoprost benzalkonium chloride (BAK) free ophthalmic solution compared to either latanoprost or bimatoprost monotherapy.

Condition or disease Intervention/treatment Phase
Glaucoma Drug: Travatan-Z Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 750 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
Study Start Date : May 2007
Actual Primary Completion Date : August 2007
Actual Study Completion Date : August 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Care Glaucoma
Drug Information available for: Travoprost
U.S. FDA Resources




Primary Outcome Measures :
  1. Ocular Surface Disease Symptoms

Secondary Outcome Measures :
  1. Intraocular pressure


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults with a clinical diagnosis of ocular hypertension, or primary open-angle, pigment dispersion or exfoliation glaucoma in at least one eye (study eye)

Exclusion Criteria:

  • Age

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00444665


Locations
United States, Minnesota
Fridley
Fridley, Minnesota, United States, 55432
Sponsors and Collaborators
Alcon Research
Investigators
Study Director: Mark Jasek, PhD Alcon Research

Publications of Results:
Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT00444665     History of Changes
Other Study ID Numbers: SMA-06-24
First Posted: March 8, 2007    Key Record Dates
Last Update Posted: November 21, 2016
Last Verified: April 2008

Keywords provided by Alcon Research:
Glaucoma

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases
Ophthalmic Solutions
Travoprost
Pharmaceutical Solutions
Antihypertensive Agents